27.39
3.51%
0.93
After Hours:
27.39
Myriad Genetics Inc stock is traded at $27.39, with a volume of 646.89K.
It is up +3.51% in the last 24 hours and down -3.32% over the past month.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
See More
Previous Close:
$26.46
Open:
$26.4
24h Volume:
646.89K
Relative Volume:
0.89
Market Cap:
$2.49B
Revenue:
$802.20M
Net Income/Loss:
$-155.20M
P/E Ratio:
-8.1518
EPS:
-3.36
Net Cash Flow:
$-141.30M
1W Performance:
+1.71%
1M Performance:
-3.32%
6M Performance:
+28.47%
1Y Performance:
+70.76%
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-21-23 | Resumed | Piper Sandler | Neutral |
Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Jul-05-23 | Resumed | JP Morgan | Underweight |
May-23-23 | Upgrade | Goldman | Sell → Buy |
Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Oct-06-22 | Initiated | Stephens | Equal-Weight |
Oct-15-21 | Resumed | Cowen | Market Perform |
Jun-15-21 | Initiated | Raymond James | Mkt Perform |
Jun-03-21 | Initiated | Goldman | Sell |
Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
Mar-12-19 | Reiterated | Needham | Strong Buy |
Jan-03-19 | Initiated | Needham | Strong Buy |
Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jan-29-18 | Initiated | Goldman | Sell |
Jan-22-18 | Reiterated | Barclays | Equal Weight |
Jan-05-18 | Initiated | BTIG Research | Buy |
Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
Aug-09-17 | Reiterated | Barclays | Equal Weight |
Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
Jan-18-17 | Initiated | Deutsche Bank | Sell |
Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
28,193 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Acquired by Hsbc Holdings PLC - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Position Reduced by D. E. Shaw & Co. Inc. - MarketBeat
Dimensional Fund Advisors LP Purchases 75,445 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Point72 Asset Management L.P. Grows Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Patent Law Trumps Policy In Myriad Cancer Gene Decision - Law360
Preventive Healthcare Technologies And Services Market Size - openPR
Profund Advisors LLC Lowers Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, Inc. (MYGN) stock: A year of ups and downs - US Post News
Financial Health Report: Myriad Genetics, Inc. (MYGN)’s Ratios Tell a Tale - The Dwinnex
Investing in Myriad Genetics, Inc. (MYGN): What You Must Know - Knox Daily
Myriad Genetics, Inc. (MYGN) can make a big difference with a little luck - SETE News
Mercury Systems, Inc. (NASDAQ:MRCY) Shares Sold by Blair William & Co. IL - Defense World
Blair William & Co. IL Buys 22,665 Shares of Symbotic Inc. (NASDAQ:SYM) - Defense World
Mirriad Advertising Schedules Live Interim Results Presentation - TipRanks
Sei Investments Co. Grows Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Uranium Unveils Historical Data Boosting Project Potential - TipRanks
Mirriad Advertising Shares Fall After Lower Revenue, Full-Year Warning - MarketWatch
Mirriad Advertising Optimistic Despite Revenue Dip - TipRanks
King Luther Capital Management Corp Buys 13,051 Shares of Mercury Systems, Inc. (NASDAQ:MRCY) - Defense World
Federated Hermes Inc. Has $1.10 Million Holdings in The E.W. Scripps Company (NASDAQ:SSP) - Defense World
Myer Holdings Full Year 2024 Earnings: EPS: AU$0.052 (vs AU$0.074 in FY 2023) - Yahoo Finance
(MYGN) Investment Report - Stock Traders Daily
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 31% Discount? - Simply Wall St
Myriad Genetics stock upside hinges on hereditary cancer segmentMorgan Stanley - Investing.com Canada
Myriad Genetics (NASDAQ:MYGN) Earns Equal Weight Rating from Analysts at Morgan Stanley - MarketBeat
Myriad Genetics a new equal-weight at Morgan Stanley: sustained growth eyed - Seeking Alpha
Myriad Genetics stock soars to 52-week high of $29.1 - Investing.com
Myriad Genetics stock soars to 52-week high of $29.1 - Investing.com India
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock - Yahoo Finance
Myriad Genetics to Share New Data Highlighting Genetic - GlobeNewswire
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference - StockTitan
Myriad Genetics (NASDAQ:MYGN) Reaches New 52-Week High at $29.30 - MarketBeat
Should You Continue to Retain MYGN Stock in Your Portfolio? - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) - Yahoo Finance
Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN) - Yahoo Finance
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) By GuruFocus - Investing.com Canada
Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN) - GuruFocus.com
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) - GuruFocus.com
Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights - GlobeNewswire Inc.
Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN) By GuruFocus - Investing.com Canada
Hereditary Testing A Game Changer for Global Finance Forecast-Myriad Genetics, Inc., CooperSurgical, Inc., Natera, Inc., Invitae Corpor – news - United States Security Bayonet ...
Myriad Genetics (NASDAQ:MYGN) Shares Down 4.9% - MarketBeat
Preventive Healthcare Technologies And Services Market Future - openPR
Myriad Genetics director sells shares worth over $270k By Investing.com - Investing.com Australia
Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN) - Yahoo Finance
Myriad Genetics director sells shares worth over $270k - Investing.com
Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN) By GuruFocus - Investing.com Canada
Myriad Genetics director sells shares worth over $270k By Investing.com - Investing.com Canada
Myriad Genetics director sells shares worth over $270k - Investing.com India
Myriad Genetics, Inc. (NASDAQ:MYGN) Director Sells $270,500.00 in Stock - MarketBeat
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):